DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Tokyo Big Sight

2016年11月13日 (日) 午前 9:30 - 2016年11月15日 (火) 午後 5:30

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

13th DIA Japan Annual Meeting 2016

Keynote Address 1

Session Chair(s)

Yoshinobu  Hirayama, PHD

Yoshinobu Hirayama, PHD

Professor, College of Pharmaceutical Sciences

Ritsumeikan University, Japan

iPS cells have dramatically shortened the distance from research to patients, and made it possible for patients to get involved in medicinal development. Research has been conducted to establish iPS cells from patients with various genetic diseases, promote scientific analysis of pathological disease conditions with known genetic etiology at the cell level, and determine a variety of factors which affect pathological conditions by analyzing somatic cells from patients with unknown genetic etiology. In addition, iPS cells are used to verify the safety of medicine as well as search for candidates for new medicine. Furthermore, they enable cell transplant therapy by combination with gene therapy. In this session, Dr. Nakahata will introduce the current situation and future possibilities of new medicine development brought by iPS cells.

Speaker(s)

Tatsutoshi  Nakahata, MD, PHD

Recent Progress in iPS Cell Research and Application

Tatsutoshi Nakahata, MD, PHD

Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan

Deputy Director and Professor

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。